Bridgeway Capital Management’s Seres Therapeutics MCRB Stock Holding History

Bridgeway Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,500	Closed	-$139K	–	1253
2025 Q2	$139K	Hold	12,500	–	–	﹤0.01%	1023
2025 Q1	$175K	Hold	12,500	–	–	﹤0.01%	950
2024 Q4	$208K	Hold	12,500	–	–	﹤0.01%	1002
2024 Q3	$237K	Buy	+12,500	New	+$254K	0.01%	1025
2024 Q2	–	Sell	-7,500	Closed	-$116K	–	1316
2024 Q1	$116K	Buy	+7,500	New	+$162K	﹤0.01%	1192
2020 Q2	–	Sell	-3,605	Closed	-$257K	–	1360
2020 Q1	$257K	Buy	+3,605	New	+$242K	0.01%	981
2019 Q4	–	Sell	-7,630	Closed	-$612K	–	1363
2019 Q3	$612K	Buy	7,630 +355	+5%	+$23.5K	0.01%	868
2019 Q2	$469K	Hold	7,275	–	–	0.01%	993
2019 Q1	$1M	Buy	+7,275	New	+$887K	0.01%	767

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Bridgeway Capital Management's MCRB Position: Q3 2025 in Review

Bridgeway Capital Management sold out of Seres Therapeutics (MCRB) in Q3 2025, closing a stake of 12,500 shares — an estimated $139K sold.

Bridgeway Capital Management first reported a position in MCRB in Q1 2019 and held it in 9 quarters. The position peaked at $1M in Q1 2019. 32 funds tracked by Wall St. Rank hold MCRB as of Q3 2025.

Bridgeway Capital Management reported no remaining Seres Therapeutics position as of Q3 2025 after selling out during the quarter.
Bridgeway Capital Management sold 12,500 Seres Therapeutics shares in Q3 2025, an estimated $139K.
Bridgeway Capital Management first reported a position in Seres Therapeutics in Q1 2019 and held it in 9 quarters.
Bridgeway Capital Management's Seres Therapeutics position peaked at $1M in Q1 2019.
32 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2025.

Based on Bridgeway Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.